BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling

Oncogene

Volumn 33, Issue 11, 2014, Pages 1418-1428

  Sung, M ^a   Giannakakou, P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BRCA1; drug resistance; dynamics; microtubule; taxane

Indexed keywords

BRCA1 PROTEIN; CASPASE 8; CISPLATIN; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA TUBULIN; MESSENGER RNA; NOCODAZOLE; PACLITAXEL;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; ENZYME BINDING; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; MICROTUBULE ASSEMBLY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TUBULIN POLYMERIZATION ASSAY; UBIQUITINATION; WESTERN BLOTTING;

APOPTOSIS; BRCA1 PROTEIN; FEMALE; HUMANS; MICROTUBULES; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84896396518     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.85     Document Type: Article

References (63)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265. (Pubitemid 38525281)
2. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696.
3. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671. (Pubitemid 46631307)
4. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313. (Pubitemid 40740554)
5. Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 2010; 363: 2200-2210.
6. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002; 8: 1073-1079. (Pubitemid 34517642)
7. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983. (Pubitemid 46594124)
8. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145-157. (Pubitemid 30105654)
9. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-1080. (Pubitemid 30616481)
10. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. (Pubitemid 39315317)
12. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. (Pubitemid 39315318)
13. Choy H. Taxanes in combined-modality therapy for solid tumors. Oncology (Williston Park) 1999; 13(Suppl 5): 23-38.
14. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13: 7413-7420.
15. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008; 108: 289-296. (Pubitemid 351311366)
16. Font A, Taron M, Gago JL, Costa C, Sanchez JJ, Carrato C et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011; 22: 139-144.
17. Reguart N, Cardona AF, Carrasco E, Gomez P, Taron M, Rosell R. BRCA1: a new genomic marker for non-small-cell lung cancer. Clin Lung Cancer 2008; 9: 331-339.
18. Saiki Y, Ogawa T, Shiga K, Sunamura M, Kobayashi T, Horii AA. Human head and neck squamous cell carcinoma cell line with acquired cis-diamminedi- chloroplatinum-resistance shows remarkable upregulation of BRCA1 and hypersensitivity to taxane. Int J Otolaryngol 2011; 2011: 521852.
19. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676. (Pubitemid 39215065)
20. Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005; 3: 531-539. (Pubitemid 41567272)
21. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285-1291. (Pubitemid 36606348)
22. Coene ED, Gadelha C, White N, Malhas A, Thomas B, Shaw M et al. A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol 2011; 192: 497-512.
23. Parvin JD. The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and centro-somes. Environ Mol Mutagen 2009; 50: 649-653.
24. Sankaran S, Crone DE, Palazzo RE, Parvin JD. BRCA1 regulates gamma-tubulin binding to centrosomes. Cancer Biol Ther 2007; 6: 1853-1857. (Pubitemid 351590396)
25. Sankaran S, Starita LM, Groen AC, Ko MJ, Parvin JD. Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination. Mol Cell Biol 2005; 25: 8656-8668. (Pubitemid 41369184)
26. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011; 8: 244-250.
27. Gascoigne KE, Taylor SS. Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14: 111-122.
28. Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene 2009; 28: 3551-3562.
29. Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol 1995; 2: 569-573.
30. Vaughan KT. TIP maker and TIP marker; EB1 as a master controller of microtubule plus ends. J Cell Biol 2005; 171: 197-200. (Pubitemid 41540012)
31. Bieling P, Laan L, Schek H, Munteanu EL, Sandblad L, Dogterom M et al. Recon-stitution of a microtubule plus-end tracking system in vitro. Nature 2007; 450: 1100-1105. (Pubitemid 350273611)
32. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003; 5: 64-70. (Pubitemid 36054331)
33. Schoffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer 2011; 47: 1006-1012.
34. Russell PA, Pharoah PD, De Foy K, Ramus SJ, Symmonds I, Wilson A et al. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 2000; 87: 317-321. (Pubitemid 30451640)
35. Lynch HT, Silva E, Snyder C, Lynch JF. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J 2008; 14: 3-13.
36. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake 2nd DD et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28: 3570-3576.
37. McAlpine JN, Porter H, Kobel M, Nelson BH, Prentice LM, Kalloger SE et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 2012; 25: 740-750.
38. Rhiem K, Todt U, Wappenschmidt B, Klein A, Wardelmann E, Schmutzler RK. Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas. Anticancer Res 2010; 30: 3445-3449.
39. Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 2011; 103: 1552-1556.
40. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009; 4e5133.
41. Parysek LM, Asnes CF, Olmsted JB. MAP 4: occurrence in mouse tissues. J Cell Biol 1984; 99(Pt 1): 1309-1315. (Pubitemid 15201616)
42. Jourdain L, Curmi P, Sobel A, Pantaloni D, Carlier MF. Stathmin: a tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 1997; 36: 10817-10821. (Pubitemid 27396235)
43. Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 2002; 99: 10855-10860.
44. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2000; 2: 709-717.
45. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71: 6019-6029.
46. Carbonaro M, Escuin D, O'Brate A, Thadani-Mulero M, Giannakakou P. Microtubules regulate hypoxia-inducible factor-1alpha protein trafficking and activity: implications for taxane therapy. J Biol Chem 2012; 287: 11859-11869.
47. Thoma CR, Matov A, Gutbrodt KL, Hoerner CR, Smole Z, Krek W et al. Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. J Cell Biol 2010; 190: 991-1003.
48. Zumbrunn J, Kinoshita K, Hyman AA, Nathke IS. Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3 beta phosphorylation. Curr Biol 2001; 11: 44-49. (Pubitemid 32062715)
49. Wen Y, Eng CH, Schmoranzer J, Cabrera-Poch N, Morris EJ, Chen M et al. EB1 and APC bind to mDia to stabilize microtubules downstream of Rho and promote cell migration. Nat Cell Biol 2004; 6: 820-830. (Pubitemid 39207247)
50. Jin S, Gao H, Mazzacurati L, Wang Y, Fan W, Chen Q et al. BRCA1 interaction of centrosomal protein Nlp is required for successful mitotic progression. J Biol Chem 2009; 284: 22970-22977.
51. Joukov V, Groen AC, Prokhorova T, Gerson R, White E, Rodriguez A et al. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 2006; 127: 539-552. (Pubitemid 44647427)
52. Hsu LC, Doan TP, White RL. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res 2001; 61: 7713-7718.
53. Chen L, Stone MC, Tao J, Rolls MM. Axon injury and stress trigger a microtubule-based neuroprotective pathway. Proc Natl Acad Sci USA 2012; 109: 11842-11847.
54. Bouissou A, Verollet C, Sousa A, Sampaio P, Wright M, Sunkel CE et al. {gamma}-Tubulin ring complexes regulate microtubule plus end dynamics. J Cell Biol 2009; 187: 327-334.
55. Xu G, Paige JS, Jaffrey SR. Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling. Nat Biotechnol 2010; 28: 868-873.
56. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001; 98: 11737-11742.
57. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991; 266: 3987-3994. (Pubitemid 21909306)
58. Marcus AI, O'Brate AM, Buey RM, Zhou J, Thomas S, Khuri FR et al. Farnesyl-transferase inhibitors reverse taxane resistance. Cancer Res 2006; 66: 8838-8846. (Pubitemid 44449202)
59. Zhou J, Vos CC, Gjyrezi A, Yoshida M, Khuri FR, Tamanoi F et al. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem 2009; 284: 9648-9655.
60. Kauh J, Chanel-Vos C, Escuin D, Fanucchi MP, Harvey RD, Saba N et al. Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer 2011; 117: 4049-4059.
61. Etienne-Manneville S. From signaling pathways to microtubule dynamics: the key players. Curr Opin Cell Biol 2010; 22: 104-111.
62. Carbonaro M, O'Brate A, Giannakakou P. Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol 2011; 192: 83-99.
63. Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 2005; 65: 3883-3893. (Pubitemid 40616370)